Terms: = Lung cancer AND BUB1B, BUBR1, 701, ENSG00000156970, SSK1, BUB1beta, MAD3L, hBUBR1, Bub1A, O60566 AND Clinical Outcome
2 results:
1. C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.
Patil NS; Zou W; Mocci S; Sandler A; Ballinger M; Flynn S; Kowanetz M; Hegde PS
PLoS One; 2021; 16(2):e0246486. PubMed ID: 33534859
[TBL] [Abstract] [Full Text] [Related]
2. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies.
Chen J; Zhao QW; Shi GM; Wang LR
J Zhejiang Univ Sci B; 2012 Nov; 13(11):875-83. PubMed ID: 23125080
[TBL] [Abstract] [Full Text] [Related]
